{"filing":{"accession_number":"0001213900-26-084263","cik":"0001892500","ticker":"CMND","company_name":"Clearmind Medicine Inc.","form":"6-K","filing_date":"2026-08-03","report_date":"2026-08-03","primary_document":"ea0300023-6k_clearmind.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1892500/000121390026084263/ea0300023-6k_clearmind.htm"},"events":[{"id":23026,"run_id":20845,"accession_number":"0001213900-26-084263","anchor_item_number":"EX-99.1","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"summary":"Clearmind Medicine announced entry into a non-binding Letter of Intent to acquire a 51% majority stake in an EV wireless charging solutions company for $2.5 million, plus a $1.5 million loan. This constitutes a material acquisition activity under Item 1.01 (entry into a material acquisition agreement), even though the LOI is non-binding and closing is subject to definitive agreements and due diligence. The transaction represents a significant strategic shift for a clinical-stage biotech company and would materially affect investor assessment.","company_name":"Clearmind Medicine Inc.","ticker":"CMND","filing_date":"2026-08-03","form":"6-K","submitted_at":null,"items":[{"id":23163,"accession_number":"0001213900-26-084263","item_number":"EX-99.1","item_title":"ea030002302ex99-1.htm","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"Clearmind Medicine announced entry into a non-binding Letter of Intent to acquire a 51% majority stake in an EV wireless charging solutions company for $2.5 million, plus a $1.5 million loan. This constitutes a material acquisition activity under Item 1.01 (entry into a material acquisition agreement), even though the LOI is non-binding and closing is subject to definitive agreements and due diligence. The transaction represents a significant strategic shift for a clinical-stage biotech company and would materially affect investor assessment.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-04T00:20:00.075093+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":23163,"accession_number":"0001213900-26-084263","item_number":"EX-99.1","item_title":"ea030002302ex99-1.htm","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"Clearmind Medicine announced entry into a non-binding Letter of Intent to acquire a 51% majority stake in an EV wireless charging solutions company for $2.5 million, plus a $1.5 million loan. This constitutes a material acquisition activity under Item 1.01 (entry into a material acquisition agreement), even though the LOI is non-binding and closing is subject to definitive agreements and due diligence. The transaction represents a significant strategic shift for a clinical-stage biotech company and would materially affect investor assessment.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-04T00:20:00.075093+00:00","company_name":"Clearmind Medicine Inc.","ticker":"CMND","filing_date":"2026-08-03"}]}